

Fish vaccination and therapy in aquaculture




Amedeo Manfrin

Istituto Zooprofilattico Sperimentale delle Venezie

National Reference Laboratory for fish, mollusc and crustacean diseases


**II Webinar of the WOA National Focal Points for Aquatic Animals in Europe
Online 05/12/2024**





The main species farmed are freshwater finfish above all cyprinids

FIGURE 13 WORLD AQUACULTURE PRODUCTION, 1991–2020



Algae

Cyprinids

● Bacterial diseases are still important everywhere

“bacterial pathogens cause major losses to aquaculture, comprising around 34% of total diseases”

Soibam Khogen Singh, Maibam Malemngamba Meitei, Tanmoy Gon Choudhary, Ngasotter Soibam, Pradyut Biswas, Gusheinzed Waikhom,(2022) Chapter 15 - **Bacterial diseases in cultured fishes: an update of advances in control measures**, Bacterial Fish Diseases, Academic Press,

Billions of dollars are lost every year



Main bacterial pathogens in European countries


Pathogen	Susceptible fish	Pathogen	Susceptible fish
<i>Aeromonas salmonicida</i>	Salmonids	<i>Photobacterium damselae subsp. damselae</i>	Marine species
<i>Aeromonas spp. (motile)</i>	Warm water species	<i>Photobacterium damselae subsp. piscicida</i>	Marine species
<i>Edwardsiella ictaluri/E. tarda</i>	Warm water species	<i>Pseudomonas spp.</i>	Fresh water species
<i>Flavobacterium psychrophilum</i>	Salmonids	<i>Renibacterium salmoninarum</i>	Salmonids
<i>Flavobacterium columnare</i>	freshwater and ornamental species	<i>Tenacibaculum spp</i>	Marine species
<i>Francisella notuanensis</i>	Salmonids	<i>Vibrio anguillarum</i>	Marine species
<i>Lactococcus garvieae</i>	Rainbow trout Warm water species	<i>Vibrio harveyi</i>	Marine species
<i>Mycobacterium spp.</i>	Mainly ornamentals	<i>Vibrio spp</i>	Marine species
<i>Moritella viscosa</i>	Salmonids		

● Antibacterial approved in EU (European Medicine Agency-CVMP 2023)


	N	GB	GR	ES	I	F	DK	PL	CZ	D	H	FL	IE	S	HR	IS	NL	P	BG	RO
Amoxicilline		X			X															
Clortetraciline																				
Enrofloxacin																			X	X
Florfenicol	X	X	X		X	X	X		X		X				X			X	X	X
Flumequine			X	X	X	X													X	X
Oxolinic acid	X		X			F	X													
Ossitetraciline		X	X	X	X	X		X	X			X	X		X			X	X	X
Sulfam./Trim.			X		X	X				X										

Main problems to perform antimicrobial therapy: outbreak management

- It's not easy to understand when and where the disease has started.
- Only therapy with **medicated feed** is allowed.
- **Sick animals don't eat** and it's impossible to perform individual therapy (like for a cat, dog or beef).
- **Prophylactic treatment are forbidden** but you need to start with metaphylactic therapy (to avoid the spread of infectious disease to healthy fish).
- There is a real lack of veterinary medicine in Europe



Conclusions: the best solution to reduce antibiotic use is vaccination



● Vaccination: the PAST

- History of vaccination in fish started in 1938 with the first report of protective immunity in carp immunized with *Aeromonas punctate*
- In 1942 Dr Duff showed protection against *Aeromonas salmonicida* in trout immunized by parenteral inoculation and by oral administration
- The first vaccine for aquaculture (against *Yersinia ruckerii* in salmonid fish) was licensed in USA in 1976
- Introduction of adjuvants
- Improved knowledge of fish immune system




● THE PRESENT

- 1982 : 2 vaccines available - ~100 scientific publications
- 2014 : ~25 formulations available
- **2020** : > 40 formulations available - >10.000 scientific publications
- Mainly **inactivated vaccines**
- Few **live attenuated vaccines**
- IP or bath administration



Adminstration route


- Bath/immersion
- Intraperitoneal
- Intramuscular
- Oral administration



GALT-Gut Associated Lymphoid Tissue



DNA-VACCINE



Uttaranchal (P.G.) College Of Bio-Medical Sciences & Hospital

Advantage:

- Low doses
- Rapid and long lasting protection
- Cheap and safe
- Stable

Based on the concept that deoxyribonucleic acid (DNA) can be utilized **alone** as vaccine

Naked plasmid DNA following uptake in cells of the vaccinated host mediates expression of the viral protein and therefore trigger the immunoresponse

Disadvantage:


- Not applicable to all pathogens
- Regulatory constraints

● ORAL VACCINES

- *Yersinia ruckeri* – oral vaccine for trout containing inactivated bacteria
- IPN - oral vaccine for salmon containing capsid VP2 – VP3 protein IPNV, (expressed in *Pichia pastoris*), encapsulated in alginate microspheres
- Piscirickettsiosis-oral vaccine containing inactivated *P. salmonid* feed incorporated
- Promising experimental results of orally administered DNA plasmids against VNN and VHS



● Low response by oral vaccination



GALT-Gut Associated Lymphoid Tissue



NEXT FRONTIERS

DIVA STRATEGY

- Differenziating **I**nfected from **V**accinated **A**nimals
- This strategy is largely used for mammals/birds, are there possible application for fish?
- **RNA vaccine**

VACCINE AGAINST PARASITE



University of Bergen, Department of Biology

Commercial vaccines authorized in Europe - 2024

Patogeno	Specie ittica	Stato europeo
<i>A. salmonicida</i>	Atlantic salmon	PT
<i>A. salmonicida</i> + <i>V.anguillarum</i> O1,O2	Atlantic salmon	DK,FI,IS,NO
<i>A. salmonicida</i> , <i>L.anguillarum</i> O1, O2 α , <i>V. salmonicida</i> , <i>Moritella viscosa</i>	Atlantic salmon	DK,FI,IS,NO
<i>A. salmonicida</i> , <i>L.anguillarum</i> O1, O2 α , <i>V. salmonicida</i> , <i>Moritella viscosa</i> , IPN Virus serotype Sp e A2	Atlantic salmon	IE,NO
<i>Lactococcus garvieae</i>	Rainbow trout	FR,EL, I,PT,ES
<i>Moritella viscosa</i>	Atlantic salmon	Norway
<i>Ph. damsela</i> subsp. <i>piscicida</i>	Sea bass	FR, EL, ES, CY
<i>Streptococcus parauberis</i>	Turbot	FR,EL,PT,ES
<i>Tenacibaculum</i> spp.	Turbot	ES
<i>V. anguillarum</i> + <i>Ph. piscicida</i>	sea bass	HR, I;FR,EL;ES
<i>V. anguillarum</i> + <i>V. ordalii</i>	Rainbow trout	CY,FR,EL,I
<i>V. anguillarum</i> + <i>V. ordalii</i>	Rainbow trout	CY,FR,EL,I,PT,ES
<i>V. anguillarum</i> O1 strainAL 112	Sea bass	HR, EL;PT,ES
<i>V. anguillarum</i> O1,O2 <i>V.salmonicida</i> , <i>A. salmonicida</i> , <i>M. viscosa</i> + IPN	Atlantic salmon	IE,UK
<i>V. anguillarum</i> O1,O2 <i>V.salmonicida</i> , <i>A. salmonicida</i> , <i>M. viscosa</i> + IPN+Infectious Salmon AnemiaVirus (ISAV)	Atlantic salmon	NO
<i>V. anguillarum</i> O1,O2 α e O2 β strain	Sea bass, turbot	FR,EL
<i>V. anguillarum</i> , <i>Ph. damsela</i> , <i>A. salmonicida</i>	sea bass	ES
<i>V. anguillarum</i> , <i>V.salmonicida</i> , <i>A. salmonicida</i> , <i>M. viscosa</i>	Atlantic salmon	
<i>V. anguillarum</i> , <i>V.salmonicida</i> , <i>A. salmonicida</i> , <i>M. viscosa</i> + IPN	Atlantic salmon	Norway
<i>Yersinia ruckeri</i> biotype 1 and 2	Atlantic salmon, Rainbow trout	CZ,FR,FI,DE,I,NO,PT,SK,ES,UK
<i>Yersinia ruckeri</i> O1 b	Atlantic salmon, Rainbow trout	CZ,F,D,Gr,IE, I, NO, PL, PT,SK,UK

● Autogenous vaccines available in EU 2023 (EMAV paper 082023)

- Autogenous vaccines against **Francisella orientalis** subsp nov. in **Tilapia** (*Oreochromis niloticus*)
- Autogenous vaccines against **Lactococcus garvieae** in **fish**
- Autogenous vaccines against **Streptococcus agalactiae** in **tilapia**
- **Tilapia Lake Virus (TiLV)** in **Tilapia** (*Oreochromis niloticus*)
- Autogenous vaccines against **ISKNV (Infectious Spleen and Kidney Necrosis Virus)** in **Tilapia** (*Oreochromis niloticus*)
- Autogenous vaccines against ***Aeromonas veronii*** in **fish**
- Autogenous vaccines against ***Vibrio harveyi*** in **fish**
- Autogenous vaccine against ***V. anguillarum*** in **Atlantic cod**
- Autogenous vaccine against **Pasteurella spp. (*Pasteurella skyensis* and *Pasteurella atlantica*)** genomovar salmonicida in **Atlantic salmon**
- Autogenous vaccine against ***Moritella viscosa*** in **Atlantic salmon**

● No money...no vaccines..quite expensive to register a new VMPs




Cost for new MA (Dir 2001/82, Art. 12)

Part of Dossier	Costs in 1.000 €
Part I: administrative data	~25-35
Part II: Quality of the product	~200-300
Part III: Toxicology	~250
Target Animal Safety	~150
User and Environmental Safety	~500-1.000
Part IV: Efficacy	~250-1.000
Fees at Authorities	~ 50-200
Project Management, Dossier Preparation, Meetings etc.	100-250
Total development costs:	1.000-2.500

13

THANK YOU FOR YOUR ATTENTION!



Amedeo Manfrin

Istituto Zooprofilattico Sperimentale

delle Venezie - IZSve

+39 049 8084458

manfrin@izsvenezie.it